Page last updated: 2024-09-04

glucagon and ao 128

glucagon has been researched along with ao 128 in 6 studies

Compound Research Comparison

Studies
(glucagon)
Trials
(glucagon)
Recent Studies (post-2010)
(glucagon)
Studies
(ao 128)
Trials
(ao 128)
Recent Studies (post-2010) (ao 128)
26,0391,4983,05425686124

Protein Interaction Comparison

ProteinTaxonomyglucagon (IC50)ao 128 (IC50)
Maltase-glucoamylase, intestinalHomo sapiens (human)1.3
Lysosomal alpha-glucosidaseHomo sapiens (human)2.835
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)1.676
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)0.4471

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Daimon, M; Fukase, N; Igarashi, M; Manaka, H; Sasaki, H; Sugiyama, K; Takahashi, H; Tominaga, M; Yamatani, K1
Arnold, R; Fuder, H; Göke, B; Kleist, P; Littke, T; Lücker, PW; Stridde, E; Theiss, U; Wieckhorst, G1
Hazama, M; Moritoh, Y; Takeuchi, K1
Inoue, M1
Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M1
Cho, KY; Nakamura, A; Nomoto, H; Ono, Y1

Trials

3 trial(s) available for glucagon and ao 128

ArticleYear
Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.
    Digestion, 1995, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Cyclohexanols; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Insulin; Male; Peptide Fragments; Protein Precursors

1995
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:16

    Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged

2012
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:8

    Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin

2013

Other Studies

3 other study(ies) available for glucagon and ao 128

ArticleYear
Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
    Diabetes research and clinical practice, 1992, Volume: 15, Issue:3

    Topics: Adult; Blood Glucose; Cyclohexanols; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycoside Hydrolase Inhibitors; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Kinetics; Male; Peptide Fragments; Protein Precursors; Reference Values; Sucrose; Time Factors

1992
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 329, Issue:2

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Time Factors

2009
The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:3

    Topics: Aged; Blood Glucose; Breakfast; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Lunch; Male; Meals; Middle Aged; Postprandial Period; Triglycerides

2014